Micro
Developing
Active
JPM micro: Price target trimmed
Gaining traction — growing article coverage and momentum.
Score
0.4
Velocity
▲ 0.0
Articles
5
Sources
1
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Financials | +14.5% |
Sentiment Timeline
Sector Performance
Event Timeline
Top Movers
| Ticker | Sector | Change |
|---|---|---|
| Financials | +14.5% |
🤖
AI Overview
What happened: On April 15, Truist analysts lifted their price target on JPMorgan Chase & Co. (JPM) to $332 from $323, maintaining a 'Hold' rating. This follows JPM's recent financial results. Meanwhile, Barclays raised its price target on Johnson & Johnson (JNJ) to $255 from $234, citing strong pharmaceutical momentum.
Market impact: The price target increases reflect analysts' positive views on these blue-chip stocks. JPM, one of the world's largest financial institutions, saw a boost in its valuation, while JNJ, a healthcare giant, received a price target hike due to its strong pharmaceutical division.
What to watch next: JPM's next earnings release is scheduled for July 14, which will provide further insight into the bank's performance. Additionally, investors should monitor JNJ's progress in its pharmaceutical segment, with specific attention to its drug pipeline and any regulatory updates.
Market impact: The price target increases reflect analysts' positive views on these blue-chip stocks. JPM, one of the world's largest financial institutions, saw a boost in its valuation, while JNJ, a healthcare giant, received a price target hike due to its strong pharmaceutical division.
What to watch next: JPM's next earnings release is scheduled for July 14, which will provide further insight into the bank's performance. Additionally, investors should monitor JNJ's progress in its pharmaceutical segment, with specific attention to its drug pipeline and any regulatory updates.
AI Overview as of Apr 22, 2026
Timeline
First SeenApr 07, 2026
Last UpdatedApr 07, 2026